Product image of Ikatybant Ranbaxy (Icatibant) supplied by GNH India

Ikatybant Ranbaxy

Active Ingredient:
Icatibant
Origin:
EU

Ikatybant Ranbaxy (Icatibant)

Icatibant, the active ingredient in Ikatybant Ranbaxy, is a bradykinin B2 receptor antagonist presented as a sterile aqueous solution for subcutaneous injection. It is used to treat hereditary angioedema caused by C1‑inhibitor deficiency, helping patients who experience recurrent swelling attacks of the skin, gastrointestinal tract, or airway.

GNH India supplies Ikatybant Ranbaxy as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide, with support for regulatory documentation and cold‑chain logistics where required.

Manufacturer / TM Owner

Ranbaxy Poland Sp. Zo.O

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Icatibant is indicated for the treatment of hereditary angioedema, a bradykinin‑mediated swelling disorder.

  • Hereditary angioedema type I: Reduces frequency and severity of acute swelling episodes.
  • Hereditary angioedema type II: Provides rapid relief of airway and facial edema.
  • Acute hereditary angioedema attacks: Offers prompt symptom control during an attack.

How It Works

  • Icatibant selectively blocks the bradykinin B2 receptor, preventing bradykinin from binding and triggering vasodilation and increased vascular permeability. By inhibiting this pathway, the drug curtails the cascade that leads to the rapid swelling characteristic of hereditary angioedema.

Side Effects

Icatibant may cause a range of adverse reactions following subcutaneous administration.

Common Side Effects

  • Injection site pain: mild to moderate discomfort at the injection site.
  • Redness or erythema: localized skin reddening.
  • Swelling at injection site: transient local edema.
  • Nausea: occasional gastrointestinal upset.
  • Headache: mild to moderate headache.
  • Dizziness: transient light‑headedness.

Serious or Rare Side Effects

  • Anaphylaxis: severe allergic reaction requiring immediate medical attention.
  • Hypotension: sudden drop in blood pressure.
  • Angioedema of the face or throat unrelated to hereditary attacks.
  • Severe hypersensitivity reactions: rash, fever, or organ involvement.

Precautions & Warnings

Before initiating therapy, clinicians should assess patient suitability and monitor for potential complications.

  • Patient assessment: confirm diagnosis of hereditary angioedema prior to use.
  • Allergy screening: avoid in individuals with known hypersensitivity to icatibant or formulation excipients.
  • Pregnancy: prescribe only if the potential benefit justifies any potential risk to the fetus.
  • Concomitant ACE inhibitors: monitor closely for additive bradykinin effects.
  • Renal or hepatic impairment: adjust monitoring as clinical condition warrants.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Icatibant may interact with other medications that influence the bradykinin pathway or hemodynamic status.

Major Interactions (Avoid)

  • ACE inhibitors: concurrent use can increase bradykinin levels and heighten the risk of angioedema.
  • Angiotensin receptor blockers (ARBs): may also augment bradykinin‑mediated effects.

Moderate Interactions (Monitor Closely)

  • Other bradykinin B2 receptor antagonists: combined effect may reduce therapeutic benefit.
  • C1‑inhibitor concentrates: concurrent use may alter clinical response.
  • Estrogen‑containing contraceptives: can increase frequency of hereditary angioedema attacks, requiring closer observation.

Frequently Asked Questions

Ikatybant Ranbaxy contains icatibant, which is prescribed to treat hereditary angioedema caused by C1‑inhibitor deficiency. It helps control acute swelling episodes affecting the skin, gastrointestinal tract, and airway, reducing the severity and duration of attacks.

Icatibant works by selectively blocking the bradykinin B2 receptor. By preventing bradykinin from binding, it stops the cascade that leads to vasodilation and increased vascular permeability, thereby limiting the rapid swelling that characterises hereditary angioedema.

The dose of Ikatybant Ranbaxy is determined by the prescribing clinician based on the patient’s condition, weight, and severity of attacks. It is administered as a subcutaneous injection, and the exact regimen should follow the prescriber’s instructions.

Limited clinical data are available for icatibant in pregnancy and lactation. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and any required import documentation.

The primary alternative is C1‑inhibitor concentrate, which replaces the deficient protein. Icatibant, by contrast, blocks the downstream bradykinin receptor, offering a rapid, protein‑free option that can be self‑administered. Choice of therapy depends on clinical response, patient preference, and specific contraindications.

Ikatybant Ranbaxy should be stored refrigerated at 2‑8 °C. Keep the product in its original packaging, protect it from light, and avoid freezing or shaking the vial. If temporary temperature excursions occur, consult the supplier before use.

The medication is supplied as a sterile solution for subcutaneous injection. It can be administered by a healthcare professional or, after proper training, self‑injected into the abdomen or thigh using the pre‑filled syringe provided with the product.

Serious risks include anaphylactic reactions, severe hypersensitivity, and unexpected angioedema unrelated to hereditary attacks. Patients should be monitored for signs of systemic allergic response, such as difficulty breathing, swelling of the face or throat, and rapid onset of hypotension.

Ikatybant should not be used by individuals with known hypersensitivity to icatibant or any excipients in the formulation. Caution is also advised for patients currently taking ACE inhibitors or those with uncontrolled cardiovascular instability, and the decision should be guided by a physician.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Icatibant

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT